B lymphocytes promote lymphogenous metastasis of lymphoma and melanoma

Neoplasia

Volumn 13, Issue 8, 2011, Pages 748-757

  Ruddell, Alanna ^a   Harrell, Maria I ^a   Furuya, Momoko ^a   Kirschbaum, Sara B ^a   Iritani, Brian M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELL EXPANSION; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; LUNG METASTASIS; LYMPH FLOW; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; LYMPHOMA; LYMPHOMA CELL; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; SPLEEN METASTASIS;

EID: 80051484018     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.11756     Document Type: Article

References (55)

1. Kawada K and Taketo MM (2011). Significance and mechanism of lymph node metastasis in cancer progression. Cancer Res 65, 9789-9798.
2. Nathanson SD (2003). Insights into the mechanisms of lymph node metastasis. Cancer 98, 413-423.
3. Morton DL, Hoon DS, Cochran AJ, Turner RR, Essner R, Takeuchi H, Wanek LA, Glass E, Foshag LJ, Hsueh EC, et al. (2003). Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 238, 538-549.
4. Turner RR, Ollila DW, Krasne DL, and Giuliano AE (1997). Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 226, 271-278.
5. Halsted WS (1907). I. The results of radical operations for the cure of carcinoma of the breast. Ann Surg 46, 1-19.
6. Fisher B (1980). Laboratory and clinical research in breast cancer-a personal adventure: the David A. Karnofsky Memorial Lecture. Cancer Res 40, 3863-3874.
7. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, and Morrow M (2011). Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305, 569-575.
8. Sleeman JP and Thiele W (2009). Tumor metastasis and the lymphatic vasculature. Int J Cancer 125, 2747-2756.
9. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Banerji S, Huarte J, Montesano R, Jackson DG, et al. (2001). Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 20, 672-682.
10. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, and Detmar M (2001). Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7, 192-198.
11. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, and Achen MG (2001). VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7, 186-191.
12. Burton JB, Priceman SJ, Sung JL, Brakenhielm E, An DS, Pytowski B, Alitalo K, and Wu L (2008). Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res 68, 7828-7837.
13. He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, and Alitalo K (2002). Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 94, 819-825.
14. Lin J, Lalani AS, Harding TC, Gonzalez M, Wu WW, Luan B, Tu GH, Koprivnikar K, VanRoey MJ, He Y, et al. (2005). Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res 65, 6901-6909.
15. Mead MJ, Nathanson SD, Lee M, and Peterson E (1985). Prophylactic lymphadenectomy for B16 melanoma in C57/BL6 mice: survival based on size and heterogeneous variant of the primary. J Surg Res 38, 319-327.
16. Rebhun RB, Lazar AJ, Fidler IJ, and Gershenwald JE (2008). Impact of sentinel lymphadenectomy on survival in a murine model of melanoma. Clin Exp Metastasis 25, 191-199.
17. Shayan R, Achen MG, and Stacker SA (2006). Lymphatic vessels in cancer metastasis: bridging the gaps. Carcinogenesis 27, 1729-1738.
18. Wong SY and Hynes RO (2006). Lymphatic or hematogenous dissemination: how does a metastatic tumor cell decide? Cell Cycle 5, 812-817.
19. Aslakson CJ and Miller FR (1992). Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52, 1399-1405.
20. Nathanson SD, Haas GP, Mead MJ, and Lee M (1986). Spontaneous regional lymph node metastases of three variants of the B16 melanoma: relationship to primary tumor size and pulmonary metastases. J Surg Oncol 33, 41-45.
21. He Y, Karpanen T, and Alitalo K (2004). Role of lymphangiogenic factors in tumor metastasis. Biochim Biophys Acta 1654, 3-12.
22. Stacker SA, Baldwin MW, and Achen MC (2002). The role of tumor lymphangiogenesis in metastatic spread. FASEB J 16, 922-934.
23. Sundar SS and Ganesan TS (2007). Role of lymphangiogenesis in cancer. J Clin Oncol 25, 4298-4307.
24. Ruddell A, Mezquita P, Brandvold KA, Farr A, and Iritani BM (2003). B lymphocyte- specific c-Myc expression stimulates early and functional expansion of the vasculature and lymphatics during lymphomagenesis. Am J Pathol 163, 2233-2245.
25. Fidler IJ (1975). Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res 35, 218-224.
26. Harrell MI, Iritani BM, and Ruddell A (2007). Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis. Am J Pathol 170, 774-786.
27. Ruddell A, Harrell MI, Minoshima S, Maravilla KR, Iritani BM, White SW, and Partridge SC (2008). Dynamic contrast-enhanced magnetic resonance imaging of tumor-induced lymph flow. Neoplasia 7, 706-713.
28. [Ruddell A, Kelly-Spratt KS, Furuya M, Parghi SS, and Kemp CJ (2008). p19/ Arf and p53 suppress sentinel lymph node lymphangiogenesis and carcinoma metastasis. Oncogene 27, 3145-3155.
29. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, and Brinster RL (1985). The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318, 533-538.
30. + T-cell/dendritic cell interactions in vivo. Cell Immunol 214, 110-122.
31. Schmitt CA, Rosenthal CT, and Lowe SW (2000). Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 6, 1029-1035.
32. [Kruisbeek A (2000). Isolation and fractionation of mononuclear cell populations. In Current Protocols in Immunology. John Wiley and Sons Inc, Philadelphia, PA. pp. 3.1.1.-3.5.5.
33. [Parish CR and Warren HS (2001). Use of the intracellular fluorescent dye CFSE to monitor lymphocyte migration and proliferation. In Current Protocols in Immunology. John Wiley and Sons, Philadelphia, PA. pp. 4.9.1-4.9.10.
34. [Iritani BM and Eisenman RN (1999). c-Myc enhances protein synthesis and cell size during B lymphocyte development. Proc Natl Acad Sci USA 96, 13180-13185.
35. [Overwijk WW and Restifo NP (2000). B16 as a mouse model for human melanoma. In Current Protocols in Immunology. John Wiley and Sons Inc, Philadelphia, PA. pp. 20.21-20.29.
36. Furuya M, Kirschbaum SB, Paulovich A, Pauli BU, Zhang H, Alexander JS, Farr AG, and Ruddell A (2010). Lymphatic endothelial murine chloride channel calcium-activated 1 is a ligand for leukocyte LFA-1 and Mac-1. J Immunol 185, 5769-5777.
37. Wiley HE, Gonzalez EB, Maki W, Wu MT, and Hwang ST (2001). Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst 93, 1638-1643.
38. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, and Adams JM (1988). The Em-c-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med 167, 353-371.
39. Giavazzi R and Garofalo A (2001). B16 melanoma metastasis. In Methods in Molecular Medicine. Vol. 58. SA Brooks and U Schumacher (Eds). Humana Press, Inc, Totowa, NJ. pp. 223-229.
40. Thornbury KD, McHale NG, Allen JM, and Hughes G (1990). Nerve-mediated contractions of sheep mesenteric lymph node capsules. J Physiology (Lond) 422, 513-522.
41. de Visser KE, Korets LV, and Coussens LM (2005). De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7, 411-423.
42. Brown DM, Fisher TL, Wei C, Frelinger JG, and Lord EM (2001). Tumours can act as adjuvants for humoral immunity. Immunology 102, 486-497.
43. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, and Karin M (2010). Bcell- derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464, 302-305.
44. Refaeli Y, Field KA, Turner BC, Trumpp A, and Bishop JM (2005). The protooncogene MYC can break B cell tolerance. Proc Natl Acad Sci USA 102, 4097-4102.
45. Cohen JN, Guidi CJ, Tewalt EF, Qiao H, Rouhani SJ, Ruddell A, Farr AG, Tung KS, and Engelhard VH (2010). Lymph node-resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation. J Exp Med 207, 681-688.
46. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, and Tubiana M (1971). Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31, 1860-1861.
47. Rassiga AL (1980). Advances in adult non-Hodgkin's lymphoma. Current concepts of classification, diagnosis, and management. Arch Intern Med 140, 1647-1651.
48. Kadowaki I, Ichinohasama R, Harigae H, Ishizawa K, Okitsu Y, Kameoka J, and Sasaki T (2005). Accelerated lymphangiogenesis in malignant lymphoma: possible role of VEGF-A and VEGF-C. Br J Haematol 130, 869-877.
49. Angeli V, Ginhoux F, Llodra J, Quemeneur L, Frenette PS, Skobe M, Jessburger R, Merad M, and Randolph GJ (2006). B cell-driven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization. Immunity 24, 203-215.
50. Li J, Kuzin I, Moshkani S, Proulx ST, Xing L, Skrombolas D, Dunn R, Sanz I, Schwarz EM, and Bottaro A (2010). Expanded CD23(+)/CD21(hi) B cells in inflamed lymph nodes are associated with the onset of inflammatory-erosive arthritis in TNF-transgenic mice and are targets of anti-CD20 therapy. J Immunol 184, 6142-6150.
51. Proulx ST, Kwok E, You Z, Beck CA, Shealy DJ, Ritchlin CT, Boyce BF, Xing L, and Schwarz EM (2007). MRI and quantification of draining lymph node function in inflammatory arthritis. Ann N Y Acad Sci 1117, 106-123.
52. Tan TT and Coussens LM (2007). Humoral immunity, inflammation and cancer. Curr Opin Immunol 19, 209-216.
53. Das Roy L, Pathangey LB, Tinder TL, Schettini JL, Gruber HE, and Mukherjee P (2009). Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis. Breast Cancer Res 11, R56-R60.
54. Franklin J, Lunt M, Bunn D, Symmons D, and Silman A (2007). Influence of inflammatory polyarthritis on cancer incidence and survival: results from a community-based prospective study. Arthritis Rheum 56, 790-798.
55. Ioachim HL and Ratech HI (2002). Ioachim's Lymph Node Pathology. Lippincott Williams and Wilkins, Philadelphia, PA.